Skip to main content
. 2020 Jul 22;11:313. doi: 10.1186/s13287-020-01834-0

Fig. 2.

Fig. 2

iMSC-sEV treatment reduces tissue loss in the chronic stage of ischemic stroke and promotes long-term neurological recovery. a Representative images of T2-MRI scan (left two columns) performed on days 2 and 28, as well as MAP-2 immunostaining (Right column) on day 28 after MCAO. Dashed line (red and white): infarct border. CL, contralateral side. IL, ipsilateral side. Scale bar = 2 mm. b Quantification analysis of the percentage of infarct volume on day 2 and day 28 after MCAO. N = 8 rats per group. Behavior tests were performed by using mNSS score (c) and foot-fault test (d) before and up to 28 days after MCAO. N = 5 rats for sham group. N = 10 rats for vehicle and iMSC-sEV groups. Data are presented as mean ± SD. *P < 0.05. n.s indicates no significant difference